Zoetis and Voyce launch pain study in dogs; Sequent picks up Topkim for $7.1M; U.S. partners with Ireland on animal-health research;

> Zoetis ($ZTS) has launched a one-year study that will use the Voyce Health Monitor to collect data on pain management in dogs with osteoarthritis. Release

> India's Sequent Scientific acquired Turkey's Topkim, a maker of 67 drugs and vaccines for food animals, for 20.7 million Turkish lira ($7.1 million). Article

> The U.S. State Department announced it has formed a research partnership with Ireland's agriculture industry focused largely on animal nutrition, reproduction and health. Article

> The Texas A&M College of Veterinary Medicine & Biomedical Sciences received $1.2 million from the Department of Homeland Security's Science and Technology Directorate and the Institute for Infectious Diseases to develop a program that will teach animal researchers to commercialize their discoveries. Article

> U.K.-based veterinary drugmaker Tangerine Group plans to open a U.S. subsidiary in Atlanta in February. Article

> France reported its first outbreak of bird flu in 8 years--the strain H5N1, which has killed 22 chickens belonging to a single family. Article

> Australia's Regeneus announced that it has initiated a trial of its cancer vaccine, Kvax, in combination with chemotherapy in 45 dogs with lymphoma, who will be treated at the Small Animal Specialist Hospital in Sydney. Article

> Blue Buffalo is recalling one lot of Cub Size Wilderness Wild Chews Bones due to possible contamination with Salmonella. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…